Extended anticoagulation therapy for the primary and secondary prevention of venous thromboembolism

Drugs

Volumn 65, Issue 3, 2005, Pages 303-311

  Blanchard, Elizabeth ^a   Ansell, Jack ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ALANINE AMINOTRANSFERASE; ANTITHROMBIN; ANTIVITAMIN K; D DIMER; ENOXAPARIN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PLACEBO; PROTEIN C; PROTEIN S; REVIPARIN; THROMBOCYTE FACTOR 4; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; BLEEDING; BRAIN HEMORRHAGE; CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; FOLLOW UP; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERCOAGULABILITY; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LIVER DYSFUNCTION; LONG TERM CARE; META ANALYSIS; ORTHOPEDIC SURGERY; PRIMARY PREVENTION; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SECONDARY PREVENTION; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; POLYSACCHARIDES; POSTOPERATIVE CARE; RECURRENCE; VENOUS THROMBOSIS;

EID: 13544259685     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565030-00001     Document Type: Review

References (35)

1. Prandoni P, Lensing AWA, Cogo A, et al. The long term clinical course of acute deep venous thrombosis. Ann Intern Med 1996 Jul; 125 (1): 1-7
2. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001 Jan; 119 (1 Suppl.): 132S-75S
3. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Anti-thrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126: 338S-400S
4. Douketis JD, Eikelboom JW, Quinlan DJ, et al. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement. Arch Intern Med 2002 Jul; 162: 1465-71
5. Hull RD, Pineo GF, Stein PD. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001 Nov; 135: 858-69
6. Prandoni P, Bruchi O, Sabbion P, et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty. Arch Intern Med 2002 Sep; 162: 1966-71
7. Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement: Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 2001 Mar; 83-A: 336-45
8. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomized trials. Lancet 2001 Jul; 358: 9-15
9. Samama CM, Vray M, Barre J, et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low molecular weight heparin with oral anticoagulant. Arch Intern Med 2002 Oct; 162: 2191-6
10. Turpie AGG. Pentasaccharides. Semin Hematol 2002 Jul; 39: 158-71
11. Turpie AGG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip replacement surgery: a randomized double-blind trial. Lancet 2002 May; 359: 1721-6
12. Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip replacement surgery: a randomized double-blind comparison. Lancet 2002 May; 359: 1515-720
13. Bauer KA, Eriksson BI, Lassen MR. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective knee surgery. N Engl J Med 2001 Nov; 345: 1305-10
14. Eriksson BI, Bauer KA, Lassen MR. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip fracture surgery. N Engl J Med 2001 Nov; 345: 1298-304
15. Eriksson BI, Lassen MR, for the PENTHIFRA Plus investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery. Arch Intern Med 2003 Jun; 163: 1337-42
16. Linkins LA, Choi PT, Douketis JD. Clinical Impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003 Dec; 139 (11): 893-900
17. Baglin T, Luddington R, Brown K, et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003 Aug; 362: 523-6
18. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis. Arch Intern Med 2000 Mar; 160: 769-74
19. Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001 May; 103: 2453-60
20. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992 Oct; 340: 873-6
21. Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal vein thrombosis. Thromb Haemost 1995 Aug; 74 (2): 606-11
22. Schulman S, Rhedin AS, Lindmarker P, et al., and The Duration of Anticoagulation Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995 Jun; 332: 1661-5
23. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999 Mar; 340 (12): 901-7
24. Agnelli G, Prandoni P, Santamaria MG. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001 Jul; 345 (3): 165-16
25. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003 Apr; 348 (15): 1425-34
26. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin for long term prevention of recurrent venous thromboembolism. N Engl J Med 2003 Aug; 349 (7): 631-9
27. Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998 Oct 1; 92 (7): 2353-8
28. Gustafsson D, Elg M. The pharmacodynamics and pharmcokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res 2003 Jul; 109: S9-15
29. Schulman S, Wählander K, Lundstrom T, et al., for the THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003 Oct; 349 (18): 1713-21
30. Ridker PM. Long term low-dose warfarin is effective in the prevention of recurrent venous thromboembolism: yes. J Thromb Haemost 2004 Jul; 2: 1034-7
31. Agnelli G. Long term low-dose warfarin is effective in the prevention of recurrent venous thromboembolism: no. J Thromb Haemost 2004 Jul; 2: 1038-40
32. Kovacs MJ. Long term low-dose warfarin is effective in the prevention of recurrent venous thromboembolism: no. J Thromb Haemost 2004 Jul; 2: 1041-3
33. Eichinger S, Minar E, Bialonczyk C, et al. D-Dimer levels and risk of recurrent venous thromboembolism. JAMA 2003 Aug; 290 (8): 1071-4
34. Cosmi B, Legnani M, Valdre G, et al. D-dimer and residual vein thrombosis assessed at 3 months after anticoagulation withdrawal are independent risk factors for recurrent venous thromboembolism [abstract no. OC151]. J Thromb Haemost 2003 Jul; 1 Suppl. 1
35. Prandoni P, Lensing AW, Prins MH, et al. Residual vein thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002 Dec; 137: 955-60